# Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

> **NCT06611813** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant Chemotherapy in Combination with Toripalimab
- **DRUG:** HR+ HER2 breast cancer

## Key facts

- **NCT ID:** NCT06611813
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2026-06
- **Final completion:** 2029-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611813, "Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06611813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*